Abstract : Cancer is a disease in humans that can cause death it has become one of the world's major health issues. One of the causes of cancer is an infectious agent. Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) are infectious agents that can cause liver cancer. GLOBOCAN 2018 provides an overview of the incidence and mortality rates for 36 forms of cancer in numerous nations, including ASEAN countries, including liver cancer caused by both HBV and HCV. This research aims to estimate the premature mortality cost of liver cancer caused by infectious agents (HBV and HCV) in ASEAN countries. This research is a descriptive study, based on data from the GLOBOCAN 2018 database on the incidence and mortality rates of liver cancer in ASEAN countries, divided into gender and age categories. Relative Risk (RR) from liver cancer and prevalence from each HBV and HCV for calculating Population Attributable Fractions (PAFs) were obtained by reviewing previous studies about liver cancer and also HBV and HCV. Premature mortality cost was determined by multiplying the mortality of liver cancer caused by HBV and HCV infection, the life expectancy of each ASEAN country, and the average income of each ASEAN country. Thailand has the highest premature mortality cost for male group for HBV-related liver cancer (US$ 49.32 million) and Vietnam has the highest cost for HCV infection (US$ 136.14 million). Premature mortality cost in Thailand (US$ 21.26 million) has the highest premature mortality cost for HBV-related liver cancer in females, whereas Vietnam (US$ 39.73 million) has the highest cost for HCV-related liver cancer. According to the findings of this study, the burden of liver cancer caused by HBV and HCV in ASEAN could have a significant impact on health costs and quality of life. To lower the prevalence and mortality of liver cancer caused by HBV and HCV in the future, preventing the risk factors that cause the disease should be a top priority in the national health strategy. This study has brought the burden of liver cancer to ASEAN, which will be useful in developing health policies and plans to reduce liver cancer's prevalence and death.